Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jan 10;15(1):193.
doi: 10.3390/v15010193.

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort

Vincenzo Malagnino  1   2 , Romina Salpini  3 , Elisabetta Teti  1 , Mirko Compagno  1   2 , Ludovica Ferrari  1 , Tiziana Mulas  1 , Valentina Svicher  4 , Marta Zordan  1 , Monica Basso  5 , Giuliana Battagin  6 , Sandro Panese  7 , Maria Cristina Rossi  8 , Renzo Scaggiante  9 , Daniela Zago  5 , Marco Iannetta  1   2 , Saverio Giuseppe Parisi  5 , Massimo Andreoni  1   2 , Loredana Sarmati  1   2
Affiliations
Observational Study

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort

Vincenzo Malagnino et al. Viruses. .

Abstract

The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p < 0.0001; 36th month 62.7% vs. 86.8%, p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35−14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC.

Keywords: 2DR; HBcAb; HIV/HBV; Occult Hepatitis B Infection (OBI); hepatitis B virus (HBV).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patients inclusion and exclusion algorithm.
Figure 2
Figure 2
Analysis of primary and secondary endpoints at times 24, 36, and 48 for HBcAb-positive vs. HBcAb-negative patients.
See this image and copyright information in PMC

References

    1. Platt L., French C.E., McGowan C.R., Sabin K., Gower E., Trickey A., McDonald B., Ong J., Stone J., Easterbrook P., et al. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis. J. Viral Hepat. 2019;27:294–315. doi: 10.1111/jvh.13217. - DOI - PMC - PubMed
    1. Pinchoff J., Tran O.C., Chen L., Bornschlegel K., Drobnik A., Kersanske L., Fuld J. Impact of hepatitis B on mortality and specific causes of death in adults with and without HIV co-infection in NYC, 2000–2011. Epidemiol. Infect. 2016;144:3354–3364. doi: 10.1017/S0950268816001801. - DOI - PMC - PubMed
    1. Rajbhandari R., Jun T., Khalili H., Chung R.T., Ananthakrishnan A.N. HBV/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV. J. Viral Hepat. 2016;23:820–829. doi: 10.1111/jvh.12555. - DOI - PMC - PubMed
    1. Thio C.L., Seaberg E.C., Skolasky R., Jr., Phair J., Visscher B., Muñoz A., Thomas D.L. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Lancet. 2002;360:1921–1926. doi: 10.1016/S0140-6736(02)11913-1. - DOI - PubMed
    1. Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A.S., Taormina Workshop on Occult HBV Infection Faculty Members Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 2019;71:397–408. doi: 10.1016/j.jhep.2019.03.034. - DOI - PubMed

Publication types